Home / Europa / Nederland / Intellectual Property

Intellectueel Eigendom (IE)

Advocatenkantoor in Nederland gespecialiseerd in Intellectueel Eigendom (IE)

In de kenniseconomie waarin wij leven is een groot deel van de waarde van ondernemingen toe te rekenen aan immateriële activa en goodwill. Intellectueel eigendom kan ervoor zorgen dat u uw concurrentie een stap voor blijft. Een duidelijke IE-strategie voor de exploitatie én de bescherming van uw intellectueel eigendom is daarbij onmisbaar. Zo kunt u maximaal voordeel uit het intellectueel eigendom halen. Onze 150 IE-specialisten werken vanuit meer dan 30 verschillende landen. Ze hebben met een aantal van de bekendste namen ter wereld gewerkt: van banken tot tech-bedrijven, media, pharmaceuten en FMCG-bedrijven (fast moving consumer goods). Door onze sectorgerichte aanpak begrijpen we uw commerciële belangen en dragen we bij aan het behalen van uw commerciële doelstellingen.

Een goed merk gaat niet meer uit het hoofd en hart van klanten. De juiste patenten zorgen ervoor dat anderen er niet met uw idee vandoor gaan of uw toegang tot de markt blokkeren. Auteursrechten, know-how en designs spelen binnen het intellectueel eigendom ook een grote rol. U kunt met juridische kwesties te maken krijgen als discussies over handelsnamen, de toelaatbaarheid van reclame-uitingen, slaafse nabootsing en onrechtmatige publicaties.

Wij concentreren ons op grote sectoren als lifesciences, automotive, consumentenproducten, financiële dienstverlening en media en technologie. Daardoor mag u van ons zowel diepgaande kennis van uw sector als alle juridische expertise op het gebied van intellectueel eigendom verwachten. Indien u in een geschilsituatie belandt - wordt er bijvoorbeeld inbreuk op uw rechten gemaakt, of wordt u van inbreuk beticht – dan zoeken we met u naar een oplossing en staan wij u bij in een eventuele procedure.

Een greep uit klanten die wij bedienen: Significant clients UEFA, Pioneer, Syngenta, Diageo, Ogilvy.

"The firm’s IP group is very knowledgeable about local and international patent issues."

The Legal 500 EMEA, 2024

"Its IP group is very knowledgeable about local and international patent issues."

The Legal 500 EMEA, 2024

"CMS stands out versus other law firms providing IP-related and commercial legal advice to us in that CMS has regard for the complexities of intellectual property rights in EU cross-border transactions and provides commercially effective, practical advice."

The Legal 500 EMEA, 2024

"Very friendly, diverse and approachable team boasting a wide variety of experience with all sorts of IP-related matters."

The Legal 500 EMEA, 2024

"A very friendly, diverse and approachable team boasting a wide variety of experience with all sorts of IP-related matters."

The Legal 500 EMEA, 2024

"CMS effectively marries the complexity of IP Law with commercial considerations and advises effectively as a result."

The Legal 500 EMEA, 2023 (Patents)

"The firm was quick, efficient and the end product produced was highly effective and of a great quality."

The Legal 500 EMEA, 2022

"The team provides really excellent quality advice. They are available, to the point and understand what really is important for their clients."

The Legal 500 EMEA, 2021

"Outstanding full service firm. Excellent knowledge of IE-rights and data protection."

The Legal 500 EMEA, 2020

"CMS has notable cross-border capabilities and utilises this expertise when handling IP-related cases where multi-jurisdictional infringement proceedings, EU-wide, FTO requests or product launches are concerned."

The Legal 500 EMEA, 2020

"The firm draws praise for the co-ordination of its international network."

Chambers Global, 2020

"CMS has a huge network and I can always trust to receive seamless and high-quality legal advice, regardless of borders."

Chambers Global, 2020

"The CMS team provides assistance on privacy, anti-competition, and data ownership issues."

The Legal 500 EMEA, 2019

The team "provides excellent service and has branches and partners in different jurisdictions."

Chambers Europe, 2019

"Cross-border capabilities really add to the customer experience."

Chambers Global, 2019
Aanmelden voor Intellectual Property onderwerpen
Blijf up-to-date met onze client services.
01/06/2021
CMS Intellectual Property Global Brochure
The pandemic that will define 2020 has put many types of intellectual property in the spotlight – particularly, of course, in life sciences. Who will develop an effective vaccine or vaccines for Covid-19...

Feed

07/11/2024
A clinical trial protocol as a pointer to the claimed crystalline form...
In recent decision T 1152/21, the Board of Appeal finds that a phase I and phase II clinical trial protocol provided a pointer to the claimed crystalline form of a compound, despite the lack of any trial...
24/09/2024
Priority entitlement: the EPO implements the new “rebuttable pre­sump­ti­on”...
In recent Technical Board of Appeal decision T 2360/19, the Board considered the validity of priority claims following the Enlarged Board of Appeal consolidated decision G 1/22 and G 2/22.The opposed...
09/08/2024
Antibody Appeals Uncovered
Since the first approval of Muromonab-CD3 in 1986, antibodies have become progressively more common, frequently reaching a ‘block­bus­ter’ status. According to statistics provided by Statista in March...
19/07/2024
A healthy balance between novelty and sufficiency for a claimed therapeutic...
The question of novelty and sufficiency of second medical use claims in light of clinical trial prior art has been addressed by the EPO Boards of Appeal on a number of occasions. In recent decision T...
13/06/2024
What’s in a name? The use of a product code in a clinical trial protocol...
The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant...
16/05/2024
A broader interpretation of "substance or composition" - good news for...
A recent decision from the EPO Boards of Appeal (T 1252/20) potentially paves the way for more diverse products to be patentable in Europe using the medical use claim format.The back­ground:Ar­ti­cle 53(c)...
06/05/2024
Transfer of IP rights in the Netherlands
Pa­tents: As­sign­ment 1. How may a patent be assigned (by law and/or transaction) and is it required to record the assignment in the national patent register to become effective?  The Dutch the Patent...
Comparable
11/04/2024
Navigating clinical trial disclosures: No reasonable expectation of success...
Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial...
10/04/2024
CMS adviseert Daihen Corporation bij de overname van Rolan Robotics
CMS heeft Daihen Corporation geadviseerd bij haar overname van Rolan Robotics. Daihen Corporation is een Japanse ontwikkelaar van innovatieve elektrische apparatuur, lasmachines, industriële robots en...
03/04/2024
EP Case Law in Brief: Long-felt want and inventive step
“Where the invention solves a technical problem which workers in the art have been attempting to solve for a long time, or otherwise fulfils a long-felt need, this may be regarded as an indication of...
25/03/2024
Patentability of inventions relating to diagnostic methods at the EPO (G...
Under Article 53(c) of the European Patent Convention (EPC), diagnostic methods practised on the human or animal body are excluded from patentability. The purpose behind this exclusion is to avoid patent...
18/01/2024
EP Case Law in Brief: Commercial success and inventive step
“Commercial success alone is not to be regarded as indicative of inventive step, but evidence of immediate commercial success when coupled with evidence of a long-felt want is of relevance provided...